| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/05/2006 | WO2003016493A3 Transporters and ion channels |
| 01/05/2006 | US20060004190 Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof |
| 01/05/2006 | US20060004093 obesity; antidiabetic agents; Alzheimer's disease; Huntington's disease;schizophrenia; anticancer agents; psoriasis; antiepileptic agents; strokes |
| 01/05/2006 | US20060004084 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
| 01/05/2006 | US20060004083 Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists |
| 01/05/2006 | US20060004080 Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof a JNK inhibitors and compositions and methods related thereto |
| 01/05/2006 | US20060004077 Inhibiting class II MHC-mediated activation of T cells; peptidomimetics of given sequence which include a Gpg (guanylpiperidyl glycine) unit; rheumatoid arthritis and/or multiple sclerosis; e.g. Ac-Cha-Gpg-Tic-Nle-NHCH2CH2Ph (Cha=cyclohexylalanine, Tic=3-carboxyisoquinoline, Nle=norleucine) |
| 01/05/2006 | US20060004056 Di-aryl-substituted-ethan pyridone pde4 inhibitors |
| 01/05/2006 | US20060004055 Derivative of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(piperidine-1-yl)-1H-pyrazole-3-carboxamide, the preparation and therapeutic use thereof |
| 01/05/2006 | US20060004051 Compounds |
| 01/05/2006 | US20060004034 Treating conditions associated with the nociceptin/ORL1 receptor system, e.g. pain, drug withdrawal, anxiety, muscle relaxants, anxiolytic agents; e.g. 1,1-[3-dimethylamino-3-(pyridin-2-yl)pentamethylene]-3,4-dihydro-1H-2,9-diazafluorene |
| 01/05/2006 | US20060004026 Compositions for ameliorating attention-deficient/hyperactivity disorder |
| 01/05/2006 | US20060004025 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors |
| 01/05/2006 | US20060004023 Treatment for attention-deficit hyperactivity disorder |
| 01/05/2006 | US20060004022 4-, 5-, 6- And 7-indole derivatives useful for the treatment of CNS disorders |
| 01/05/2006 | US20060004013 Cinnamide compound |
| 01/05/2006 | US20060004010 Ccr4 antagonist and medical use thereof |
| 01/05/2006 | US20060003998 2-(2-Methoxy-phenyl)-1-morpholin-2-yl-1-phenyl-ethanol hydrochloride; selective inhibitors of the reuptake of norepinephrine; in membrane cells of central nervous system; anxiolitic agent, cognition activator, psycological disorder |
| 01/05/2006 | US20060003996 Intralesional treatment of psoriasis |
| 01/05/2006 | US20060003992 New drug combinations |
| 01/05/2006 | US20060003988 Compounds capable of inhibiting immunocyte-related allergic immune reactions |
| 01/05/2006 | US20060003987 Compounds and their uses |
| 01/05/2006 | US20060003986 Such as 4-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-ylcarbamoyl)-piperidine-1-carboxylic acid tert-butyl ester; for prevention of illnesses based on the modulation of the adenosine system, such as Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain |
| 01/05/2006 | US20060003978 beta-secretase inhibitors; to reduce A beta peptide formation; to reduce amyloid beta deposits or plaques; 12-[2-(3-Ethyl-benzylamino)-1-hydroxy-ethyl]-16-fluoro-2-oxa-8,11-diaza-bicyclo[12.3.1]octadeca-1(17),14(18),15-triene-7,10-dione |
| 01/05/2006 | US20060003975 Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor |
| 01/05/2006 | US20060003937 Urocortin-III and uses thereof |
| 01/05/2006 | US20060003922 Spinner preparation machine and cavity resonator |
| 01/05/2006 | US20060003915 Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
| 01/05/2006 | US20060003410 Oxidoreductase for use in identifying modulators for prevention and treatment of diabetes, obesity, dyslipidemia, coronary heart, inflammatory and cancer disorders |
| 01/05/2006 | US20060002930 Treatment of disorders |
| 01/05/2006 | US20060002919 15625 receptor, a novel G-protein coupled receptor |
| 01/05/2006 | US20060002901 Composition containing eosinophil cationic protein |
| 01/05/2006 | US20060002894 Method for introducing a biological molecule using a viral envelope and composition and system therefor |
| 01/05/2006 | US20060002893 Targeted adenovirus vectors for delivery of heterologous genes |
| 01/05/2006 | US20060002853 Stilbene derivatives and their use for binding and imaging amyloid plaques |
| 01/05/2006 | DE102004029325A1 Use of a medicament, comprising cholinesterase inhibitor (e.g. donepezil), for the treatment of behavior disturbances and/or disturbances of cognitive functions caused due to the fetal alcohol syndrome |
| 01/05/2006 | DE102004004965B4 Verfahren zur Herstellung eines 2-(Ethoxymethyl)-tropanderivates A process for preparing a 2- (ethoxymethyl) -tropanderivates |
| 01/05/2006 | CA2735272A1 Nerve regeneration by transplanting cells expressing recombinant transforming growth factor superfamily protein |
| 01/05/2006 | CA2584493A1 Kinase inhibitors for treating cancers |
| 01/05/2006 | CA2578682A1 Composition for antianxiety drug containing vegetable essence ingredient as active ingredient, percutaneous-absorption-type antianxiety drug employing the composition, and processes for producing these |
| 01/05/2006 | CA2571949A1 Modulators of atp-binding cassette transporters |
| 01/05/2006 | CA2571718A1 Compounds for the treatment of an acute injury to the central nervous system |
| 01/05/2006 | CA2571717A1 Compounds for the treatment of inflammation of the central nervous system |
| 01/05/2006 | CA2571555A1 Diazabicyclic histamine-3 receptor antagonists |
| 01/05/2006 | CA2571505A1 New mao-b inhibitors |
| 01/05/2006 | CA2571443A1 Pyridyl piperazines for the treatment of cns disorders |
| 01/05/2006 | CA2571421A1 Compounds for immunopotentiation |
| 01/05/2006 | CA2571012A1 Tricyclic compounds and their use as mglur1 antagonists |
| 01/05/2006 | CA2570818A1 Indolylalkylamine metabolites as 5-hydroxytrytamine-6 ligands |
| 01/05/2006 | CA2570813A1 Lactam tachykinin receptor antagonists |
| 01/05/2006 | CA2568804A1 Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with a cyclic amino group as crf antagonists |
| 01/05/2006 | CA2568802A1 Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with tetrahydropyridine as crf antagonists |
| 01/05/2006 | CA2567977A1 Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
| 01/05/2006 | CA2567365A1 Use of reboxetine for the treatment of pain |
| 01/05/2006 | CA2560671A1 Crystalline forms of n-desmethylclozapine |
| 01/04/2006 | EP1612273A1 Novel physiologically active substances pf1270a, b and c |
| 01/04/2006 | EP1612270A2 Rétroviral nucleic material and nucleotide fragments, in particular associated with multiple sclerosis and/or rheumatoid arthritis, for diagnostic, prophylactic and therapeutic uses |
| 01/04/2006 | EP1612266A2 Prostaglandin reductase |
| 01/04/2006 | EP1612222A2 Olfactory and pheromones G-protein coupled receptors |
| 01/04/2006 | EP1612215A1 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 01/04/2006 | EP1612210A1 New analogs of nitrobenzylthioinosine |
| 01/04/2006 | EP1612204A1 Hydrazone derivative |
| 01/04/2006 | EP1611902A1 Preventive and/or therapeutic agent for neuropathic pain |
| 01/04/2006 | EP1611893A1 Remedy for nerve damage |
| 01/04/2006 | EP1611892A2 Pharmaceutical compositions comprising drospirenone |
| 01/04/2006 | EP1611887A2 Modulation of peroxisome proliferator-activated receptors |
| 01/04/2006 | EP1611144A1 Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists |
| 01/04/2006 | EP1611129A1 Cyclic sulfamides for inhibition of gamma-secretase |
| 01/04/2006 | EP1611121A1 Pyridazinone derivatives as cdk2-inhibitors |
| 01/04/2006 | EP1611119A1 Pi-3 kinase inhibitor prodrugs |
| 01/04/2006 | EP1611115A1 Benzothiazole derivative compounds, compositions and uses |
| 01/04/2006 | EP1611109A1 Novel quinazoline derivatives and methods of treatment related to the use thereof |
| 01/04/2006 | EP1611107A1 1,3,4-substituted pyrazoles for use as 5-ht receptor antagonists in the treatment of psychoses and neurological disorders |
| 01/04/2006 | EP1611104A1 Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists |
| 01/04/2006 | EP1611098A1 Compounds having activity at 5ht2c receptor and uses thereof |
| 01/04/2006 | EP1611096A2 Benzamide modulators of metabotropic glutamate receptors |
| 01/04/2006 | EP1611094A1 Pyrazole compounds |
| 01/04/2006 | EP1611086A1 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors |
| 01/04/2006 | EP1610810A2 Use of clusterin for the treatment and/or prevention of peripheral neurological diseases |
| 01/04/2006 | EP1610796A2 High potency dopaminergic treatment of neurological impairment associated with brain injury |
| 01/04/2006 | EP1610792A1 Calcium channel blockers comprising two benzhydril moieties |
| 01/04/2006 | EP1610791A1 Implantable polymeric device for sustained release of dopamine agonist |
| 01/04/2006 | EP1610786A1 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl-carbonyl)piperidine derivatives and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's |
| 01/04/2006 | EP1610785A2 Pharmaceutical combination for the treatment of spasticity and/or pain |
| 01/04/2006 | EP1610771A2 Use of an alpha2-adrenoceptor antagonist for the treatment of epilepsy |
| 01/04/2006 | EP1494658B1 Natural phenolic products and derivatives thereof for protection against neurodegenerative diseases |
| 01/04/2006 | EP1472514A4 Method of preparing delta-9 tetrahydrocannabinol |
| 01/04/2006 | EP1434762A4 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 01/04/2006 | EP1397153A4 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 01/04/2006 | EP1357941B1 Therapeutical use of anti-mag antibody for the treatment of ischemic stroke |
| 01/04/2006 | EP1351688A4 Urotensin-ii receptor antagonists |
| 01/04/2006 | EP1339677B1 Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis |
| 01/04/2006 | EP1311677B1 Regulation of human p2y1-like g protein-coupled receptor |
| 01/04/2006 | EP1294725B1 Multicyclic compounds and their use as inhibitors of parp, vegfr2 and mlk3 enzymes |
| 01/04/2006 | EP1294390B1 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotection from glutamate toxicity |
| 01/04/2006 | EP1242403B1 2,4-diaminopyrimidine compounds usful as immunosuppressants |
| 01/04/2006 | EP1237553B1 The combination of a serotonin reuptake inhibitor and a 5-ht 2c? antagonist, inverse agonist or partial agonist |
| 01/04/2006 | EP1212000B1 System for controlling body temperature while reducing shivering |
| 01/04/2006 | EP1189886B1 Ethanesulfonyl-piperidine derivatives |
| 01/04/2006 | EP1169298B1 Pharmaceutical compounds |